Cubist Pharmaceuticals Inc. (CBST)
-NasdaqGS 55.49 
0.54(0.96%) May 24, 4:00PM EDT|After Hours
:
56.03 0.54 (0.97%) May 24, 5:00PM EDT
| Prev Close: | 56.03 |
|---|
| Open: | 54.90 |
|---|
| Bid: | N/A |
|---|
| Ask: | 56.49 x 100 |
|---|
| 1y Target Est: | 55.71 |
|---|
| Beta: | 0.54 |
|---|
| Next Earnings Date: | 17-Jul-13 |
|---|
| Day's Range: | 54.16 - 55.64 |
|---|
| 52wk Range: | 36.73 - 56.54 |
|---|
| Volume: | 633,786 |
|---|
| Avg Vol (3m): | 878,800 |
|---|
| Market Cap: | 3.62B |
|---|
| P/E (ttm): | 30.90 |
|---|
| EPS (ttm): | 1.80 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Analysts: Williams-Sonoma Has International Growth Potential and 3 More Research Notes to Readat Wall St. Cheat Sheet(Fri, May 24)
- Priority FDA Review for Celgene's AbraxaneZacks(Fri, May 24)
- Cubist downgraded at Janney Capitalat theflyonthewall.com(Fri, May 24)
- NPS Pharma Prices OfferingZacks(Thu, May 23)
- Is There a Future for Small Pharma?at Motley Fool(Thu, May 23)
- Cubist to Present at Jefferies 2013 Global Healthcare ConferenceBusiness Wire(Thu, May 23)
- Do These Tuesday Upgrades Present a Buying Opportunity?at Motley Fool(Thu, May 23)
- Cubist Pharmaceuticals Inc. (CBST): Today's Featured Health Care Winnerat TheStreet(Wed, May 22)
- Cubist, Optimer, Trius: Antibiotic Deal Making On Tapat TheStreet(Wed, May 22)
- Cubist Rises On Unusually High Volume (CBST)at TheStreet(Tue, May 21)
- Ahead of the Bell: Analyst upgrades Cubist PharmaAP(Tue, May 21)
- Analysts' Actions: CBST CNW COH TMHC VFCTheStreet(Tue, May 21)
- Cubist price target raised to $63 from $53 at RBC Capitaltheflyonthewall.com(Tue, May 21)
- 2013 FDA Drug Approval Calendarat TheStreet(Tue, May 21)
- Cubist Pharma upgraded by Cantor FitzgeraldBriefing.com(Mon, May 20)
Key Statistics
| Forward P/E (1 yr): | 30.66 |
|---|
| P/S (ttm): | 3.87 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.23 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.38 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 1.57 |
|---|
Business Summary
Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products for various medical needs in the acute care environment in the United States.
View More